EC
CYCN icon

EcoR1 Capital’s Cyclerion Therapeutics CYCN Stock Holding History

EcoR1 Capital’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-80,314
Closed -$4.93M – 81
2021
Q3 		$4.93M Hold
80,314
– – 0.17% 42
2021
Q2 		$6.26M Hold
80,314
– – 0.23% 39
2021
Q1 		$4.48M Hold
80,314
– – 0.2% 43
2020
Q4 		$4.92M Sell
80,314
-56,800
-41% -$3.87M 0.26% 41
2020
Q3 		$16.7M Hold
137,114
– – 1.19% 21
2020
Q2 		$16.2M Hold
137,114
– – 1.2% 23
2020
Q1 		$7.27M Buy
137,114
+46,564
+51% +$3.32M 0.76% 31
2019
Q4 		$4.93M Buy
90,550
+51,740
+133% +$4.83M 0.44% 35
2019
Q3 		$9.41M Hold
38,810
– – 1.19% 20
2019
Q2 		$8.89M Buy
+38,810
New +$11M 0.9% 22

Other funds holding CYCN

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital's CYCN Position: Q4 2021 in Review

EcoR1 Capital sold out of Cyclerion Therapeutics (CYCN) in Q4 2021, closing a stake of 80,314 shares — an estimated $4.93M sold.

EcoR1 Capital first reported a position in CYCN in Q2 2019 and held it in 10 quarters. The position peaked at $16.7M in Q3 2020. 56 funds tracked by Wall St. Rank hold CYCN as of Q4 2021.

  • EcoR1 Capital reported no remaining Cyclerion Therapeutics position as of Q4 2021 after selling out during the quarter.
  • EcoR1 Capital sold 80,314 Cyclerion Therapeutics shares in Q4 2021, an estimated $4.93M.
  • EcoR1 Capital first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 10 quarters.
  • EcoR1 Capital's Cyclerion Therapeutics position peaked at $16.7M in Q3 2020.
  • 56 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2021.

Based on EcoR1 Capital's 13F filing for Q4 2021, filed 14 Feb 2022.